These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 37939446)

  • 1. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
    Incorvaia L; Perez A; Marchetti C; Brando C; Gristina V; Cancelliere D; Pivetti A; Contino S; Di Giovanni E; Barraco N; Bono M; Giurintano A; Bazan Russo TD; Gottardo A; Cutaia S; Pedone E; Peri M; Corsini LR; Fanale D; Galvano A; Scambia G; Badalamenti G; Russo A; Bazan V
    Cancer Treat Rev; 2023 Dec; 121():102650. PubMed ID: 37939446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
    Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
    Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR
    Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
    Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
    J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    Gourley C; Miller RE; Hollis RL; Ledermann JA
    Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2 D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous recombination proficiency in ovarian and breast cancer patients.
    Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
    BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
    Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.